Semaglutide regulatory status
Current status of Semaglutide in the United States: FDA approved. In sport: Not WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Draft, pending editorial review. Last verified
What is the current status of Semaglutide?
- FDA and compounding
- FDA approved products (Ozempic 2017, Rybelsus 2019, Wegovy 2021). FDA removed semaglutide from the drug shortage list on February 21, 2025; compounding by 503A pharmacies had to stop by April 22, 2025 and by 503B outsourcing facilities by May 22, 2025, except for a documented patient specific clinical need. FDA has warned about unapproved compounded and counterfeit GLP-1 products and salt forms (semaglutide sodium, semaglutide acetate) that are not the approved active ingredient. On April 30, 2026 FDA proposed not to include semaglutide on the 503B bulks list; that proposal was not final as of September 2026. Adding a vitamin such as B12 or niacinamide does not by itself make a compounded GLP-1 different from the approved drug. Under FDA's April 1, 2026 policy update, such a combination may be treated as essentially a copy when the strengths are within 10% of approved products and the route is the same, unless a prescriber documents a real difference for the individual patient. A September 2026 FDA warning letter applied this to semaglutide and tirzepatide vitamin combinations, said high production volume suggested the claimed differences were a pretext, and questioned significant-difference statements picked from preset menus on prescribing platforms.
- WADA
- Not WADA prohibited
- Access path
- Prescription from a licensed provider (in person or telehealth) filled at a retail pharmacy as Ozempic, Wegovy, or Rybelsus.
- FDA's Drug Shortages database lists Rybelsus 3 mg, 7 mg, and 14 mg tablets as To Be Discontinued, posted June 4, 2026; ask the prescriber or pharmacy which oral semaglutide product replaces them.
- Manufacturer direct-to-consumer cash pay program for Wegovy.
- Compounded semaglutide is no longer lawful for routine dispensing after the 2025 shortage resolution; ask any provider offering it what the documented clinical need is.
Full Semaglutide page: evidence, dosing in the literature, and sources
How has the status of Semaglutide changed over time?
- FDA
FDA warning letter treats GLP-1 plus vitamin combinations as essentially copies
In a warning letter dated September 18, 2026 and posted September 22, FDA said compounded tirzepatide with niacinamide and semaglutide with cyanocobalamin (vitamin B12) appeared to be essentially copies of approved drugs, that the volume produced suggested the claimed differences were a pretext, and that significant-difference statements were repeated verbatim across many records or chosen from preset menus on prescribing platforms. The letter's findings are specific to one pharmacy, but they apply FDA's April 1, 2026 policy that a combination within 10% of approved strengths by the same route may be treated as essentially a copy without a documented prescriber determination.
- FDA
FDA proposes to keep semaglutide, tirzepatide and liraglutide off the 503B bulks list
FDA proposed not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list, after tentatively finding no clinical need for outsourcing facilities to compound them from bulk. The notice was published May 1, 2026, and the comment period was extended to July 30, 2026. The proposal was not final as of September 2026. It does not change the 503A rules for patient specific compounding.
- FDA
FDA approves a 7.2 mg Wegovy dose for chronic weight management
FDA approved a higher 7.2 mg dose of Wegovy (semaglutide) injection, marketed as Wegovy HD, for weight loss and long-term maintenance of weight loss in certain adults.
- FDA
FDA approves oral semaglutide (Wegovy tablets) for weight management
In December 2025 FDA approved a once-daily oral formulation of semaglutide for chronic weight management, the first oral GLP-1 receptor agonist approved for obesity.
Regulatory: FDA approvedSource: Drugs@FDA: Wegovy (semaglutide) NDA 215256 - FDA
FDA grants accelerated approval of Wegovy for MASH with fibrosis
FDA granted accelerated approval of Wegovy (semaglutide 2.4 mg) for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis, based on histologic endpoints from the ESSENCE trial.
Regulatory: FDA approvedSource: Drugs@FDA: Wegovy (semaglutide) NDA 215256 - FDA
503B grace period for compounded semaglutide ends
FDA's enforcement discretion for 503B outsourcing facilities compounding semaglutide ended, closing the shortage-based pathway for compounded semaglutide.
- FDA
503A grace period for compounded semaglutide ends
FDA's enforcement discretion for 503A pharmacies compounding semaglutide ended. After this date 503A pharmacies may not compound copies of Ozempic or Wegovy on shortage grounds.
- FDA
FDA declares the semaglutide shortage resolved
FDA announced that the shortage of semaglutide injection (Ozempic and Wegovy) was resolved and set enforcement discretion periods: 503A pharmacies until April 22, 2025 and 503B outsourcing facilities until May 22, 2025.
- FDA
FDA approves Ozempic for chronic kidney disease in type 2 diabetes
FDA approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, based on the FLOW trial.
Regulatory: FDA approvedSource: Drugs@FDA: Ozempic (semaglutide) NDA 209637 - FDA
FDA approves Wegovy to reduce cardiovascular risk in adults with obesity
FDA approved a new indication for Wegovy (semaglutide 2.4 mg) to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, based on the SELECT trial.
- FDA
FDA warns about compounded semaglutide made with salt forms
In May 2023 FDA published its concerns about compounded semaglutide, stating it had received adverse event reports and that products made with semaglutide sodium or semaglutide acetate salts are not the same active ingredient as the approved drugs and do not meet the compounding exemption requirements.
- FDA
FDA expands Wegovy to adolescents aged 12 and older
FDA approved Wegovy (semaglutide 2.4 mg) for chronic weight management in pediatric patients aged 12 years and older with obesity, based on the STEP TEENS trial.
Regulatory: FDA approvedSource: Drugs@FDA: Wegovy (semaglutide) NDA 215256 - FDA
FDA lists semaglutide injection on the drug shortage list
In March 2022 FDA added semaglutide injection to its drug shortage list as demand for Wegovy and Ozempic outpaced supply. While a drug is in shortage, 503A and 503B compounders may prepare essentially a copy under FDA's shortage-related compounding policies.
- FDA
FDA approves Wegovy (semaglutide 2.4 mg) for chronic weight management
FDA approved once-weekly semaglutide 2.4 mg injection (Wegovy) for chronic weight management in adults with obesity or overweight with at least one weight-related condition, the first new weight-management drug approved since 2014.
Regulatory: FDA approvedSource: Drugs@FDA: Wegovy (semaglutide) NDA 215256 - FDA
FDA adds cardiovascular risk reduction to the Ozempic label
FDA approved a label expansion for Ozempic (semaglutide) to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, based on the SUSTAIN-6 trial.
Regulatory: FDA approvedSource: Drugs@FDA: Ozempic (semaglutide) NDA 209637 - FDA
FDA approves Rybelsus, the first oral GLP-1 receptor agonist
FDA approved oral semaglutide tablets (Rybelsus) for adults with type 2 diabetes, the first GLP-1 receptor agonist available in a pill rather than an injection.
Regulatory: FDA approvedSource: Drugs@FDA: Rybelsus (semaglutide tablets) NDA 213051 - FDA
FDA approves Ozempic (semaglutide) for type 2 diabetes
FDA approved once-weekly semaglutide injection (Ozempic) to improve glycemic control in adults with type 2 diabetes, the first semaglutide product to reach the US market.
Regulatory: FDA approvedSource: Drugs@FDA: Ozempic (semaglutide) NDA 209637
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for Semaglutide and the source of each dated event.
- [1]FDA prescribing information for Wegovy (semaglutide) injection and tablets, via DailyMedFDA, 2025
- [2]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding deadlinesFDA, 2025
- [3]WADA Prohibited ListWADA, 2026
- [4]FDA prescribing information for Ozempic (semaglutide) injection, via DailyMedFDA
- [5]FDA prescribing information for Rybelsus and Ozempic (semaglutide) tablets, via DailyMedFDA
- [6]FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (GLP-1 shortage status updates, including liraglutide, and the April 1, 2026 policy update on essentially copies)FDA, 2026
- [7]Federal Register 2026-08552: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (proposed May 1, 2026; comments extended to July 30, 2026)Federal Register, 2026
- [8]FDA warning letter to a compounding pharmacy on semaglutide and tirzepatide vitamin combinations (September 18, 2026)FDA, 2026
- [9]FDA Drug Shortages: semaglutide tablet (Rybelsus 3, 7, and 14 mg listed To Be Discontinued, posted June 4, 2026; checked September 27, 2026)FDA, 2026
- [10]FDA press release: FDA approves fourth product under national priority voucher program, higher dose semaglutide (March 19, 2026)FDA, 2026
From the blog
- Wegovy pill vs injection: what the trials show
Semaglutide now comes as a daily tablet and a weekly injection for weight management. We compare the trials, the label differences, and what each costs to get.
- What happened to compounded semaglutide
Compounded semaglutide went from a shortage workaround to a narrow, patient-specific exception. Here is the timeline, what FDA found, and what access looks like in 2026.
- Do GLP-1 patches work? What they contain and what the evidence says
No FDA-approved GLP-1 patch exists. Here is why GLP-1 drugs cannot pass through skin from a sticker, what patch ingredients have been tested by mouth, and how to read patch reviews.
- How to get a compounded GLP-1 prescription in 2026
Compounded semaglutide and tirzepatide are now limited to documented patient-specific needs. Here is how the lawful path works, how to check a pharmacy, and what the branded alternatives cost.